These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22214308)

  • 1. Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET.
    Jahan M; Eriksson O; Johnström P; Korsgren O; Sundin A; Johansson L; Halldin C
    EJNMMI Res; 2011 Dec; 1(1):33. PubMed ID: 22214308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET Imaging of VMAT2 with the Novel Radioligand [
    Nag S; Jahan M; Tóth M; Nakao R; Varrone A; Halldin C
    ACS Chem Neurosci; 2021 Dec; 12(24):4580-4586. PubMed ID: 34813272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass.
    Eriksson O; Jahan M; Johnström P; Korsgren O; Sundin A; Halldin C; Johansson L
    Nucl Med Biol; 2010 Apr; 37(3):357-63. PubMed ID: 20346875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
    Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
    Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
    Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.
    Li X; Chen Z; Tang J; Liu C; Zou P; Huang H; Tan C; Yu H
    Arch Pharm (Weinheim); 2014 May; 347(5):313-9. PubMed ID: 24497196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
    Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
    PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas.
    Fagerholm V; Mikkola KK; Ishizu T; Arponen E; Kauhanen S; Någren K; Solin O; Nuutila P; Haaparanta M
    J Nucl Med; 2010 Sep; 51(9):1439-46. PubMed ID: 20720057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.
    Huang ZR; Tsai CL; Huang YY; Shiue CY; Tzen KY; Yen RF; Hsin LW
    PLoS One; 2016; 11(9):e0161295. PubMed ID: 27612194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
    Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
    J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [
    Li J; Chen P; Bao Y; Sun Y; He J; Liu X
    Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeling and in vitro and in vivo evaluation of [18F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5.
    Honer M; Stoffel A; Kessler LJ; Schubiger PA; Ametamey SM
    Nucl Med Biol; 2007 Nov; 34(8):973-80. PubMed ID: 17998101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
    Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
    Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
    Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
    Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VMAT2 imaging agent, D6-[
    Zhao R; Zha Z; Yao X; Ploessl K; Choi SR; Liu F; Zhu L; Kung HF
    Nucl Med Biol; 2019; 72-73():26-35. PubMed ID: 31330409
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.